Semaglutide vs Tirzepatide for Appetite Suppression
Appetite suppression is the primary driver of weight loss on GLP-1 medications. Here is how semaglutide and tirzepatide compare for silencing hunger and food noise.
Medical Disclaimer: This comparison is for informational purposes only. Medication selection should be made with your healthcare provider.
If you are choosing between semaglutide and tirzepatide, appetite suppression is likely your top priority. Both medications are remarkably effective at reducing hunger, but they work through different mechanisms and produce different degrees of effect.
How They Suppress Appetite
- Semaglutide: Activates GLP-1 receptors in the brain's appetite centers (hypothalamus and brainstem), slows gastric emptying, and increases feelings of fullness after smaller meals
- Tirzepatide: Does everything semaglutide does plus activates GIP receptors, providing a second pathway for appetite regulation and improved satiety signaling
Clinical Trial Comparison
| Metric | Semaglutide 2.4mg | Tirzepatide 15mg |
|---|---|---|
| Average weight loss | ~15% | ~21% |
| Caloric reduction reported | ~30-35% | ~35-40% |
| Patients losing 20%+ | ~32% | ~57% |
| Appetite onset | Week 1-2 | Week 1-2 |
| Food noise reduction | Significant | Significant |
The Food Noise Effect
Both medications powerfully reduce "food noise" - the constant mental chatter about food. Patients describe this as:
- Being able to walk past the kitchen without thinking about eating
- Forgetting to eat meals because hunger does not demand attention
- Being able to stop eating mid-meal when satisfied
- No longer being controlled by cravings
- Feeling "normal" around food for the first time
Real-World Patient Reports
Semaglutide patients commonly describe a gradual reduction in appetite that strengthens with dose increases. Many find their appetite well-controlled at 1.0-1.7mg doses. The effect is described as "not being hungry" rather than "not being able to eat."
Tirzepatide patients often describe more profound appetite suppression, particularly at higher doses. Some patients need to actively remind themselves to eat. The dual mechanism may explain why many report stronger and more consistent appetite control.
The Bottom Line
Our Assessment
Tirzepatide generally produces stronger appetite suppression than semaglutide, consistent with its greater average weight loss results. However, both medications are highly effective, and some patients respond better to semaglutide. If appetite suppression is your primary goal, tirzepatide may be the stronger starting option, but semaglutide remains excellent for most patients.
Frequently Asked Questions
Which suppresses appetite more: semaglutide or tirzepatide?
Tirzepatide generally produces stronger appetite suppression, as reflected in greater average weight loss (21% vs 15% in trials). The dual GLP-1/GIP mechanism provides more comprehensive appetite control. However, individual responses vary and some patients find semaglutide equally effective.
How quickly does appetite suppression start?
Most patients notice reduced appetite within the first 1-2 weeks on either medication, even at the starting dose. Appetite suppression typically strengthens with each dose increase. Maximum effect is usually felt at the therapeutic dose range.
What is 'food noise' and does it go away on GLP-1?
Food noise refers to the constant mental preoccupation with food: thinking about what to eat next, craving specific foods, and feeling unable to stop thinking about food. Both semaglutide and tirzepatide dramatically reduce food noise for most patients, often described as the most life-changing effect of the medication.
Does appetite suppression wear off over time?
Some patients notice a mild reduction in appetite suppression after 6-12 months, though this is usually modest. Appetite rarely returns to pre-medication levels while on treatment. If effectiveness decreases significantly, your provider may adjust your dose or consider switching medications.
Find Your Best GLP-1 Fit
Trimi clinicians help you choose the right medication for your goals. Affordable treatment with personalized dosing.
Get Started TodayMore on Micro-Comparisons
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).